{
    "clinical_study": {
        "@rank": "38307", 
        "acronym": "RAPID", 
        "arm_group": {
            "arm_group_label": "Observational", 
            "description": "Long term follow-up"
        }, 
        "brief_summary": {
            "textblock": "A Phase 3b, Study of Subjects With Alzheimer's Disease Who Discontinued Treatment in\n      Bapineuzumab Phase 3 Clinical Studies (ELN115727-301/302/351) or Who Completed Studies\n      ELN115727-301 and 302 but did not Enroll in Study ELN115727-351."
        }, 
        "brief_title": "Retrieval of Patient Information After Discontinuation", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Anticipated"
        }, 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "1. Signed, dated, and written informed consent obtained from the subject and/or the\n             subject's legally acceptable representative (LAR, if applicable) in accordance with\n             local regulations.\n\n          2. Signed, dated, and written informed consent, obtained from the subject's caregiver in\n             accordance with local regulations.\n\n          3. Subject must have participated in the Study 301, 302, or 351 and have received at\n             least 1 dose of study treatment (bapineuzumab or placebo).\n\n          4. Subject must have been off treatment for at least 12 months prior to Visit 1.\n\n          5. Subjects must have a primary caregiver for the duration of the study.\n\n          6. Subject's caregiver must have the ability to assess the subject and answer questions\n             over the phone."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "55 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Subjects with Alzheimer's disease who discontinued treatment in bapineuzumab Phase 3\n        clinical studies (ELN115727-301/302/351) or who completed studies ELN115727-301 or 302 but\n        did not enroll in study ELN115727-351"
            }
        }, 
        "enrollment": {
            "#text": "169", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01658722", 
            "org_study_id": "AAB-001-ALZ-3300"
        }, 
        "intervention": {
            "arm_group_label": "Observational", 
            "intervention_name": "Bapineuzumab", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "August 24, 2012", 
        "number_of_groups": "1", 
        "official_title": "A Phase 3b Study of Subjects With Alzheimer's Disease Who Discontinued Treatment in Bapineuzumab Phase 3 Clinical Studies (ELN115727-301/302/351) or Who Completed Studies ELN15727-301 and 302 But Did Not Enroll in Study ELN115727-351", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ]
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Caregiver's assessment of a patient's need for assistance", 
            "measure": "Dependence Scale", 
            "safety_issue": "No", 
            "time_frame": "4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01658722"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "JANSSEN Alzheimer Immunotherapy Research & Development, LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "JANSSEN Alzheimer Immunotherapy Research & Development, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2012"
    }
}